Outset Medical, Inc. (NASDAQ:OM) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Five analysts give Outset Medical a consensus "Moderate Buy" (1 sell, 1 hold, 2 buy, 1 strong buy) with an average 12‑month price target of $10, though several firms (Stifel, BTIG) have recently cut targets and Weiss reaffirmed a sell.
• Stock and insider activity: OM trades near $4.32 with a 1‑year range of $3.00–$21.98 and a market cap of about $79M (negative P/E), and insiders including the CEO and General Counsel sold shares in January—insiders sold 38,783 shares in the past 90 days and now own 2.4% of the company.

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) has been given an average rating of "Moderate Buy" by the five analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $10.00.

Several equities research analysts have issued reports on OM shares. Stifel Nicolaus dropped their target price on shares of Outset Medical from $14.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, January 7th. Wall Street Zen upgraded shares of Outset Medical from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Royal Bank Of Canada restated a "sector perform" rating and issued a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. BTIG Research lowered their price objective on shares of Outset Medical from $17.00 to $15.00 and set a "buy" rating for the company in a report on Thursday, February 12th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Outset Medical in a report on Friday, March 27th.

Outset Medical Trading Up 2.9%

Shares of Outset Medical stock opened at $4.32 on Friday. Outset Medical has a 1 year low of $3.00 and a 1 year high of $21.98. The firm has a market cap of $79.10 million, a PE ratio of -0.64 and a beta of 1.97. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.67 and a quick ratio of 5.40. The company has a 50 day simple moving average of $3.77 and a two-hundred day simple moving average of $6.60.

Insider Transactions at Outset Medical

In other news, General Counsel John L. Brottem sold 9,314 shares of the business's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the sale, the general counsel directly owned 36,957 shares in the company, valued at approximately $189,219.84. The trade was a 20.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Leslie Trigg sold 11,794 shares of Outset Medical stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the completion of the transaction, the chief executive officer directly owned 107,823 shares in the company, valued at approximately $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 38,783 shares of company stock worth $183,958. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Hsbc Holdings PLC purchased a new position in shares of Outset Medical in the fourth quarter worth $46,000. Aristides Capital LLC purchased a new position in shares of Outset Medical in the fourth quarter worth $177,000. XTX Topco Ltd increased its stake in shares of Outset Medical by 876.9% in the fourth quarter. XTX Topco Ltd now owns 100,612 shares of the company's stock worth $373,000 after buying an additional 90,313 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Outset Medical in the fourth quarter worth $186,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Outset Medical in the fourth quarter worth $74,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.